These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32519208)

  • 1. Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia.
    Kossmann C; Heller J; Brüne M; Schulz C; Heinze M; Cordes J; Mühlbauer B; Rüther E; Timm J; Gründer G; Juckel G
    Psychiatr Q; 2021 Mar; 92(1):177-191. PubMed ID: 32519208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia.
    Vauth R; Carpiniello B; Turczyński J; Ivanov M; Cherubin P; Lahaye M; Schreiner A
    Int J Methods Psychiatr Res; 2021 Jun; 30(2):e1855. PubMed ID: 33355966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment.
    Hunter R; Barry S
    Eur Psychiatry; 2012 Aug; 27(6):432-6. PubMed ID: 21602034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia.
    Jelastopulu E; Giourou E; Merekoulias G; Mestousi A; Moratis E; Alexopoulos EC
    BMC Psychiatry; 2014 Jul; 14():197. PubMed ID: 25005616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The illness and everyday living: close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophrenia.
    Schaub D; Brüne M; Jaspen E; Pajonk FG; Bierhoff HW; Juckel G
    Eur Arch Psychiatry Clin Neurosci; 2011 Mar; 261(2):85-93. PubMed ID: 20652295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial.
    Veselinović T; Scharpenberg M; Heinze M; Cordes J; Mühlbauer B; Juckel G; Habel U; Rüther E; Timm J; Gründer G;
    Eur Neuropsychopharmacol; 2019 Jun; 29(6):720-739. PubMed ID: 30981585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial functioning as a personal resource promoting a milder course of schizophrenia.
    Neumann E; Rixe J; Haussleiter IS; Macdonald L; Rabeneck E; Bender S; Möller J; Schormann M; Wrona E; Köhne M; Driessen M; Juckel G
    J Psychiatr Res; 2022 Apr; 148():121-126. PubMed ID: 35123323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
    Lipkovich IA; Deberdt W; Csernansky JG; Sabbe B; Keefe RS; Kollack-Walker S
    BMC Psychiatry; 2009 Jul; 9():44. PubMed ID: 19602273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
    Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
    BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.
    Gründer G; Heinze M; Cordes J; Mühlbauer B; Juckel G; Schulz C; Rüther E; Timm J;
    Lancet Psychiatry; 2016 Aug; 3(8):717-729. PubMed ID: 27265548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
    Patrick DL; Burns T; Morosini P; Rothman M; Gagnon DD; Wild D; Adriaenssen I
    Curr Med Res Opin; 2009 Feb; 25(2):325-38. PubMed ID: 19192977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
    Barnes TR; Leeson VC; Paton C; Costelloe C; Simon J; Kiss N; Osborn D; Killaspy H; Craig TK; Lewis S; Keown P; Ismail S; Crawford M; Baldwin D; Lewis G; Geddes J; Kumar M; Pathak R; Taylor S
    Health Technol Assess; 2016 Apr; 20(29):1-46. PubMed ID: 27094189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia.
    Juckel G; Schaub D; Fuchs N; Naumann U; Uhl I; Witthaus H; Hargarter L; Bierhoff HW; Brüne M
    Schizophr Res; 2008 Sep; 104(1-3):287-93. PubMed ID: 18595665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones.
    Iasevoli F; Giordano S; Balletta R; Latte G; Formato MV; Prinzivalli E; De Berardis D; Tomasetti C; de Bartolomeis A
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():34-48. PubMed ID: 26320028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia.
    Juckel G; Morosini PL
    Curr Opin Psychiatry; 2008 Nov; 21(6):630-9. PubMed ID: 18852573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
    Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
    CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning.
    Bucci P; Mucci A; van Rossum IW; Aiello C; Arango C; Baandrup L; Buchanan RW; Dazzan P; Demjaha A; Díaz-Caneja CM; Giordano GM; Glenthøj BY; Leucht S; McGuire P; Rodriguez-Jimenez R; Vignapiano A; Kahn RS; Galderisi S
    Eur Neuropsychopharmacol; 2020 May; 34():76-86. PubMed ID: 32291210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.